Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Macrolide Antibiotics Market

ID: MRFR/Pharma/16780-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026

US Macrolide Antibiotics Market Research Report: Size, Share, Trend Analysis By Drugs (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin, Telithromycin), By Route of Administration (Oral, Parenteral), By Indication (Infection Due to Mycoplasma Pneumoniae, Legionella Sp, Bordetella Pertussis, Symptomatic Cat-Scratch Disease, Bacillary Angiomatosis, Peliosis Hepatis in Patients with AIDS, Cerebral Toxoplasmosis, Uncomplicated Skin Infections, Others) and By End Users (Hospitals, Dermatology Clinics, Pharmaceutical Companies, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Macrolide Antibiotics Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Food, Beverages & Nutrition, BY Drug (USD Billion)
  49.     4.1.1 Azithromycin
  50.     4.1.2 Clarithromycin
  51.     4.1.3 Erythromycin
  52.     4.1.4 Fidaxomicin
  53.     4.1.5 Telithromycin
  54.   4.2 Food, Beverages & Nutrition, BY Route of Administration (USD Billion)
  55.     4.2.1 Oral
  56.     4.2.2 Parenteral
  57.   4.3 Food, Beverages & Nutrition, BY Indication (USD Billion)
  58.     4.3.1 Infection Due to Mycoplasma Pneumoniae
  59.     4.3.2 Legionella Sp, or Bordetella Pertussis
  60.     4.3.3 Symptomatic Cat-Scratch Disease
  61.     4.3.4 Bacillary Angiomatosis
  62.     4.3.5 Peliosis Hepatis in Patients with AIDS
  63.     4.3.6 Cerebral Toxoplasmosis
  64.     4.3.7 Uncomplicated Skin Infections
  65.     4.3.8 Others
  66.   4.4 Food, Beverages & Nutrition, BY End User (USD Billion)
  67.     4.4.1 Hospitals
  68.     4.4.2 Dermatology Clinics
  69.     4.4.3 Pharmaceutical Companies
  70.     4.4.4 Others
  71. 5 SECTION V: COMPETITIVE ANALYSIS
  72.   5.1 Competitive Landscape
  73.     5.1.1 Overview
  74.     5.1.2 Competitive Analysis
  75.     5.1.3 Market share Analysis
  76.     5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  77.     5.1.5 Competitive Benchmarking
  78.     5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  79.     5.1.7 Key developments and growth strategies
  80.       5.1.7.1 New Product Launch/Service Deployment
  81.       5.1.7.2 Merger & Acquisitions
  82.       5.1.7.3 Joint Ventures
  83.     5.1.8 Major Players Financial Matrix
  84.       5.1.8.1 Sales and Operating Income
  85.       5.1.8.2 Major Players R&D Expenditure. 2023
  86.   5.2 Company Profiles
  87.     5.2.1 Pfizer Inc (US)
  88.       5.2.1.1 Financial Overview
  89.       5.2.1.2 Products Offered
  90.       5.2.1.3 Key Developments
  91.       5.2.1.4 SWOT Analysis
  92.       5.2.1.5 Key Strategies
  93.     5.2.2 AstraZeneca PLC (GB)
  94.       5.2.2.1 Financial Overview
  95.       5.2.2.2 Products Offered
  96.       5.2.2.3 Key Developments
  97.       5.2.2.4 SWOT Analysis
  98.       5.2.2.5 Key Strategies
  99.     5.2.3 Merck & Co Inc (US)
  100.       5.2.3.1 Financial Overview
  101.       5.2.3.2 Products Offered
  102.       5.2.3.3 Key Developments
  103.       5.2.3.4 SWOT Analysis
  104.       5.2.3.5 Key Strategies
  105.     5.2.4 Bristol-Myers Squibb Company (US)
  106.       5.2.4.1 Financial Overview
  107.       5.2.4.2 Products Offered
  108.       5.2.4.3 Key Developments
  109.       5.2.4.4 SWOT Analysis
  110.       5.2.4.5 Key Strategies
  111.     5.2.5 AbbVie Inc (US)
  112.       5.2.5.1 Financial Overview
  113.       5.2.5.2 Products Offered
  114.       5.2.5.3 Key Developments
  115.       5.2.5.4 SWOT Analysis
  116.       5.2.5.5 Key Strategies
  117.     5.2.6 Teva Pharmaceutical Industries Ltd (IL)
  118.       5.2.6.1 Financial Overview
  119.       5.2.6.2 Products Offered
  120.       5.2.6.3 Key Developments
  121.       5.2.6.4 SWOT Analysis
  122.       5.2.6.5 Key Strategies
  123.     5.2.7 Novartis AG (CH)
  124.       5.2.7.1 Financial Overview
  125.       5.2.7.2 Products Offered
  126.       5.2.7.3 Key Developments
  127.       5.2.7.4 SWOT Analysis
  128.       5.2.7.5 Key Strategies
  129.     5.2.8 Sanofi S.A. (FR)
  130.       5.2.8.1 Financial Overview
  131.       5.2.8.2 Products Offered
  132.       5.2.8.3 Key Developments
  133.       5.2.8.4 SWOT Analysis
  134.       5.2.8.5 Key Strategies
  135.     5.2.9 GSK PLC (GB)
  136.       5.2.9.1 Financial Overview
  137.       5.2.9.2 Products Offered
  138.       5.2.9.3 Key Developments
  139.       5.2.9.4 SWOT Analysis
  140.       5.2.9.5 Key Strategies
  141.   5.3 Appendix
  142.     5.3.1 References
  143.     5.3.2 Related Reports
  144. 6 LIST OF FIGURES
  145.   6.1 MARKET SYNOPSIS
  146.   6.2 US MARKET ANALYSIS BY DRUG
  147.   6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  148.   6.4 US MARKET ANALYSIS BY INDICATION
  149.   6.5 US MARKET ANALYSIS BY END USER
  150.   6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
  151.   6.7 RESEARCH PROCESS OF MRFR
  152.   6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
  153.   6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  154.   6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
  155.   6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
  156.   6.12 FOOD, BEVERAGES & NUTRITION, BY DRUG, 2024 (% SHARE)
  157.   6.13 FOOD, BEVERAGES & NUTRITION, BY DRUG, 2024 TO 2035 (USD Billion)
  158.   6.14 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  159.   6.15 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  160.   6.16 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 (% SHARE)
  161.   6.17 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 TO 2035 (USD Billion)
  162.   6.18 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 (% SHARE)
  163.   6.19 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 TO 2035 (USD Billion)
  164.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  165. 7 LIST OF TABLES
  166.   7.1 LIST OF ASSUMPTIONS
  167.     7.1.1
  168.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  169.     7.2.1 BY DRUG, 2025-2035 (USD Billion)
  170.     7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  171.     7.2.3 BY INDICATION, 2025-2035 (USD Billion)
  172.     7.2.4 BY END USER, 2025-2035 (USD Billion)
  173.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  174.     7.3.1
  175.   7.4 ACQUISITION/PARTNERSHIP
  176.     7.4.1

US Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Drug (USD Billion, 2025-2035)

  • Azithromycin
  • Clarithromycin
  • Erythromycin
  • Fidaxomicin
  • Telithromycin

Food, Beverages & Nutrition By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Parenteral

Food, Beverages & Nutrition By Indication (USD Billion, 2025-2035)

  • Infection Due to Mycoplasma Pneumoniae
  • Legionella Sp, or Bordetella Pertussis
  • Symptomatic Cat-Scratch Disease
  • Bacillary Angiomatosis
  • Peliosis Hepatis in Patients with AIDS
  • Cerebral Toxoplasmosis
  • Uncomplicated Skin Infections
  • Others

Food, Beverages & Nutrition By End User (USD Billion, 2025-2035)

  • Hospitals
  • Dermatology Clinics
  • Pharmaceutical Companies
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓